Vera Therapeutics is trading 10.28% up now at $31.86 after the FDA published an integrated review describing a favorable profile for Trutakna, its recently approved kidney-disease therapy.
- Cantor Fitzgerald characterized the review as indicating a competitive profile, directly supporting the August 14, 2026 rally.
- Investors are reassessing August 10 second-quarter results, including a narrower-than-expected $1.52-per-share loss despite higher launch-related expenses.